Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Patients (PTS) with Metastatic or Surgically Unresectable (M/UR) Urothelial Carcinoma (UC) and Selected FGFR Gene Alterations (FGFRALT): Phase 3 THOR Study

被引：0

作者：

Imkamp, Florian ^{[1
]}

Loriot, Yohann ^{[2
]}

Necchi, Andrea ^{[3
]}

Park, Se Hoon ^{[4
]}

Huddart, Robert ^{[5
]}

Burgess, Earle ^{[6
]}

Fu, Min ^{[7
]}

Santiago-Walker, Ademi ^{[7
]}

Mukhopadhyay, Sutapa ^{[7
]}

Naini, Vahid ^{[7
]}

Deprince, Kris ^{[8
]}

Monga, Manish ^{[7
]}

Siefker-Radtke, Arlene ^{[9
]}

机构：

[1] Hannover Univ, Dept Urol, Med Ctr, Hannover, Germany

[2] Inst Gustave Roussy, Villejuif, France

[3] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[4] Samsung Med Ctr, Seoul, South Korea

[5] Inst Canc Res, London, England

[6] Carolinas HealthCare Syst, Levine Canc Inst, Charlotte, NC USA

[7] Janssen Res & Dev, San Diego, CA USA

[8] Janssen Res & Dev, Beerse, Belgium

[9] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

488

引用

页码：78 / 78

页数：1

共 36 条

[21] Fibroblast growth factor receptor 3 (FGFR3) alterations in PROOF 302: A phase III trial of infigratinib (BGJ398) as adjuvant therapy in patients (pts) with invasive urothelial carcinoma (UC)
Grivas, Petros
Daneshmand, Siamak
Makarov, Vladimir
Bellmunt, Joaquim
Sridhar, Srikala S.
Sonpavde, Guru P.
Cole, Suzanne
Tripathi, Abhishek
Faltas, Bishoy Morris
Lerner, Seth P.
Fleming, Mark T.
Loriot, Yohann
Meeks, Joshua J.
Master, Viraj A.
Davis, Kimberlee
Van Veenhuyzen, David Friedrich
Afifi, Shugufa
Pal, Sumanta Kumar
Gupta, Shilpa
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[22] First in human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced urothelial carcinoma (UC) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations.
Garmezy, Benjamin
Perez, Cesar Augusto
Kato, Shumei
Sharma, Manish
Quah, Cheng Seok
Tam, Betty
Severson, Paul
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[23] Phase II/III study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1/3 mRNA expression
Sternberg, C. N.
Bellmunt, J.
Nishiyama, H.
Petrylak, D. P.
Quinn, D. I.
Nakajima, K.
Lu, C.
Holynskyj, A.
ANNALS OF ONCOLOGY, 2018, 29 : 331 - 331
[24] A phase I study of cabozantinib plus nivolumab (CaboNivo) and cabonivo plus ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic (m) urothelial carcinoma (UC) and other genitourinary (GU) tumors.
Apolo, Andrea B.
Mortazavi, Amir
Stein, Mark N.
Davarpanah, Nicole N.
Nadal, Rosa Maria
Parnes, Howard L.
Ning, Yangmin M.
Francis, Deneise C.
Cordes, Lisa M.
Berniger, Marilise Anne
Steinberg, Seth M.
Agarwal, Piyush K.
Bagheri, Mohammadhadi H.
Nanda, Swati
Monk, Paul
Lancaster, Tiffany
Moore, Tina
Costello, Rene
Bottaro, Donald P.
Pal, Sumanta K.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[25] Impact of primary tumor location on efficacy and safety of pembrolizumab (pembro) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) enrolled in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-045 trials.
O'Donnell, Peter H.
Balar, Arjun Vasant
Castellano, Daniel E.
De Wit, Ronald
Vaughn, David J.
Powles, Thomas
Vuky, Jacqueline
Lee, Jae-Lyun
Fradet, Yves
Bellmunt, Joaquim
Fong, Lawrence
Petrylak, Daniel P.
Gerritsen, Winald R.
Quinn, David I.
Culine, Stephane
Bajorin, Dean F.
Xu, Jin Zhi
Imai, Kentaro
Moreno, Blanca Homet
Grivas, Petros
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[26] Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with intermediaterisk non-muscle-invasive bladder cancer (IR-NMIBC) with FGFR3/2 alterations (alt) in THOR-2: Cohort 3 interim analysis.
Daneshmand, Siamak
Zaucha, Renata
Gartrell, Benjamin Adam
Lotan, Yair
Hussain, Syed A.
Lee, Eugene K.
Procopio, Giuseppe
Galanternik, Fernando
Naini, Vahid
Carcione, Jenna
Triantos, Spyros
Baig, Mahadi
Maranchie, Jodi K.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[27] Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA plus CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse study
Siefker-Radtke, Arlene O.
Powles, Thomas
Moreno, Victor
Kang, Taek Won
Cicin, Irfan
Girvin, Angela
Akapame, Sydney
Triantos, Spyros
O'Hagan, Anne
Zhu, Wei
Tammaro, Meggan
Loriot, Yohann
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[28] FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression
Sternberg, Cora N.
Petrylak, Daniel P.
Bellmunt, Joaquim
Nishiyama, Hiroyuki
Necchi, Andrea
Gurney, Howard
Lee, Jae-Lyun
van der Heijden, Michiel S.
Rosenbaum, Eli
Penel, Nicolas
Pang, See-Tong
Li, Jian-Ri
del Muro, Xavier Garcia
Joly, Florence
Papai, Zsuzsanna
Bao, Weichao
Ellinghaus, Peter
Lu, Chengxing
Sierecki, Mitchell
Coppieters, Sabine
Nakajima, Keiko
Ishida, Tatiane Cristine
Quinn, David, I
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (03) : 629 - +
[29] Phase I study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor, in patients with advanced cholangiocarcinoma, urothelial carcinoma and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations
Garmezy, B.
Borad, M.
Lin, C. C.
Chen, L. T.
Perez, C. A.
Kato, S.
Tam, B.
Severson, P.
Quah, C. S.
Harding, J. J.
ANNALS OF ONCOLOGY, 2023, 34 : S231 - S232
[30] A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SOC) versus SOC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901).
Galsky, Matt D.
Powles, Thomas
Li, Shengting
Hennicken, Delphine
Sonpavde, Guru
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)

← 1 2 3 4 →